Clinical Trial

Mapsd Dual-target cTBS (Auditory Cortex and M1) for Generalized Anxiety Disorder

Study acronym: Dual-ACM1-GAD
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to investigate the effectiveness of a dual-target non-invasive brain stimulation technique called continuous Theta Burst Stimulation (cTBS) for treating Generalized Anxiety Disorder (GAD). The researchers will use a neuronavigation system, which acts like a GPS for the brain, to guide the stimulation to two specific targets: the left auditory association cortex and the primary motor cortex (M1). Participants will be randomly assigned to one of two groups. One group will receive active dual-target cTBS treatment, while the other will receive a sham (placebo) stimulation that feels similar but has no therapeutic effect. The treatment will be given three times a day for seven consecutive days. Before and after the treatment period, all participants will complete clinical questionnaires to measure their anxiety and undergo Magnetic Resonance Imaging (MRI) scans to help researchers understand how cTBS affects brain activity.
Trial Details
NCT Number NCT07403591
Lead Sponsor Anhui Medical University
Conditions Generalized Anxiety Disorder
Enrollment 60 participants
Start Date 2026-03-01
Primary Completion 2027-03-01 (estimated)
Study Completion 2027-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-11